Highly active antiretroviral therapy: Pharmacoeconomic issues in the management of HIV infection

PharmacoEconomics

Volumn 19, Issue 7, 2001, Pages 709-713

  Sendi, P ^a   Palmer, A J ^b   Gafni, A ^a   Battegay, M ^c  

^a MCMASTER UNIVERSITY   (Canada)

^b IQVIA   (United States)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; INDINAVIR; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

AIDS RELATED COMPLEX; COST BENEFIT ANALYSIS; COST CONTROL; DRUG EFFICACY; DRUG MECHANISM; EMPLOYABILITY; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MORBIDITY; MORTALITY; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PRODUCTIVITY; REVIEW;

EID: 0034919021     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200119070-00001     Document Type: Review

References (21)

1. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: Prospective multicentre study. Swiss HIV Cohort Study
2. Estimating AIDS-free survival in a severely immunosuppressed asymptomatic HIV-infected population in the era of antiretroviral triple combination therapy. Swiss HIV Cohort Study
3. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens
4. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel
5. Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV Cohort Study
6. Cost effectiveness of combination HIV therapy: 3 years later
7. Combination antiretroviral therapy in HIV infection: An economic perspective
8. Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: Application to a clinical trial
9. The cost effectiveness of antiretroviral regimens for the treatment of HIV/AIDS
10. Economic analysis of initial HIV treatment: Efavirenz- versus indinavir-containing triple therapy
11. Costs of HIV medical care in the era of highly active antiretroviral therapy
12. Decreased medical expenditures for care of HIV-seropositive patients: The impact of highly active antiretroviral therapy at a US Veterans Affairs Medical Center
13. Reduction in human immunodeficiency virus patient hospitalizations and non-traumatic mortality after adoption of highly active antiretroviral therapy
14. Quality of life in asymptomatic patients with early HIV infection initiating antiretroviral therapy. Swiss HIV Cohort Study
15. Discounting in the economic evaluation of health care interventions
16. Accounting for future costs in medical cost-effectiveness analysis
17. Effect of future costs on cost-effectiveness of medical interventions among young adults: The example of intensive therapy for type 1 diabetes mellitus
18. Cost effectiveness/utility analyses: Do current decision rules lead us to where we want to be?
19. From cost-effectiveness ratio to resource allocation, where to draw the line?
20. Cost effectiveness ratios: In a league of their own
21. Differences in attitudes, knowledge and use of economic evaluations in decision-making in The Netherlands: The Dutch results from the EUROMET Project